6/24/2023 0 Comments 4d pharma oncology![]() ![]() Two of these patients have now been treated for over 18 months and have had further target tumor reductions or extended disease control since the last update. Three Part A patients with RCC and NSCLC that were previously reported to have experienced clinical benefit continue on the study. These include the first signals of anti-tumor activity for the combination in bladder cancer, adding to the previously reported activity in RCC and NSCLC in patients in Part A. Target tumor reductions in Part B patients have been observed as patients reach the first scheduled restaging timepoint (nine weeks). Recruitment will continue up to a total of 30 patients in each of these indications. A total of 12 patients with RCC, nine patients with non-small cell lung cancer (NSCLC) and three bladder cancer patients have been enrolled in Part B to date. The safety review following the first Part B cohort of 10 renal cell carcinoma (RCC) patients has been completed indicating no dose limiting toxicities. ![]() In May 2020 the successful completion of Part A and initiation of Part B was announced.Ģ4 additional patients across five active US sites have now been treated in Part B of this ongoing study. This study is comprised of two parts - Part A, an initial safety phase assessing dose-limiting toxicities of the combination, and the Part B cohort expansion phase to assess clinical benefit in addition to safety. MRx0518 is in an ongoing Phase I/II clinical trial in combination with immune checkpoint inhibitor (ICI) Keytruda® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with advanced malignancies who have previously progressed on ICI therapy. This will support 4D pharma's continued productive engagement with regulatory authorities to develop the clinical strategy to bring this novel therapeutic to patients suffering from a range of cancers." ![]() We look forward to generating more clinical data from our ongoing studies of MRx0518 in multiple different tumor types and treatment settings. "As 4D pharma extends its leading position in this exciting and rapidly maturing field, we see the next 12 months as being instrumental for the space. Alex Stevenson, Chief Scientific Officer, 4D pharma. This clinical and development progress has been achieved in spite of the headwinds of COVID-19," said Dr. We have generated additional safety and efficacy data, building on the positive data from both the monotherapy and KEYTRUDA combination studies last year. "4D pharma has continued to make excellent progress with the MRx0518 development program on multiple fronts. 3, 2021 /PRNewswire/ - Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518. ![]()
0 Comments
Leave a Reply. |